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Abstract
Background: This study was conducted to identify potential biomarkers that could be used to evaluate disease
progression and monitor responses to enzyme replacement therapy (ERT) in patients with mucopolysaccharidosis
(MPS) IVA.
Methods: Levels of 88 candidate biomarkers were compared in plasma samples from 50 healthy controls and 78
MPSIVA patients not receiving ERT to test for significant correlations to the presence of MPSIVA. MPSIVA samples
were also tested for correlations between candidate biomarkers and age, endurance, or urinary keratin sulfate (KS)
levels. Then, levels of the same 88 analytes were followed over 36 weeks in 20 MPSIVA patients receiving ERT to
test for significant correlations related to ERT, age, or endurance.
Results: Nineteen candidate biomarkers were significantly different between MPSIVA and unaffected individuals. Of
these, five also changed significantly in response to ERT: alpha-1-antitrypsin, eotaxin, lipoprotein(a), matrix
metalloprotein (MMP)-2, and serum amyloid P. Three of these were significantly lower in MPSIVA individuals versus
unaffected controls and were increased during ERT: alpha-1-antitrypsin, lipoprotein(a), and serum amyloid P.
Conclusions: Candidate biomarkers alpha-1-antitrypsin, lipoprotein(a), and serum amyloid P may be suitable
markers, in addition to urinary KS, to follow the response to ERT in MPSIVA patients.
Background
Mucopolysaccharidosis (MPS) IVA (OMIM #253000),
also known as Morquio A syndrome, is an autosomal
recessive lysosomal storage disorder caused by deficient
activity of N-acetylgalactosamine-6-sulfatase (GALNS)
[1]. GALNS catalyzes the degradation of the glycosami-
noglycans (GAGs), KS and chondroitin-6-sulfate (CS). In
individuals affected with MPSIVA, KS and CS accumu-
late in the tissues, causing skeletal dysplasia, coarse facial
features, restricted growth and short stature, joint hyper-
mobility, valvular heart disease, pulmonary disease,
obstructive sleep apnea, hepatomegaly, corneal clouding,
hearing loss, and poorly formed teeth [1]. Because more
than 150 mutations in the gene encoding GALNS have
been identified, there is considerable clinical heterogene-
ity ranging from mild to severe based on the residual
GALNS activity [1,2]. The International Morquio Regis-
try and the Morquio Clinical Assessment Program (Mor-
CAP, also known as MOR-001) found considerable
morbitity and mortality in MPSIVA individuals, including
frequent surgical procedures, limited mobility, poor
endurance and pulmonary function, and death in the sec-
ond or third decade of life for patients with a severe phe-
notype (about 68% of MPSIVA patients) [1,3]. Urinary
GAG testing is used to screen for MPSIVA, with enzyme
activity measurement in blood or fibroblasts to confirm
diagnosis [1,2]. The incidence of MPSIVA ranges from 1
in 40,000 to 1 in 450,000 live births [1,2].
Currently there is no treatment for MPSIVA, only sup-
portive measures such as surgeries for skeletal dysplasia,
oxygen for poor lung function, and antibiotics for lung
infections [1,2]. However, ERT with recombinant human
(rh) GALNS (BMN110) is under clinical development,
ERT provides a supply of the deficient enzyme and is
available for MPS I, MPS II, and MPS VI [4]. * Correspondence: efoehr@bmrn.com
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edly decreased storage in visceral organs, heart valves,
ligaments, connective tissues, and brain [6]. ERT
(rhGALNS, BMN110) for MPSIVA is evaluated in a
Phase I/II human trial. The clinical trial is a multicenter,
open-label, dose-escalation study to evaluate safety, tol-
erability, and efficacy of BMN 110 in patients with MPS
IVA (clinical trial #NCT00884949) between 5 and 18
years of age [7]. A global double blind, randomized, pla-
cebo-controlled Phase III study of BMN 110 in MPSIVA
was initiated in 2011 [8].
With ERT in development for MPS IVA, identification
of biomarkers to evaluate disease progression and
response to treatment becomes more important. To date,
KS has been identified as an important biomarker for
MPS IVA [9] as it accumulates in the tissues, particularly
the cartilage, cornea, and heart valves, in MPS IVA
patients [10]. KS storage in the cartilage causes cartilage
disruption, which contributes to increased circulating
levels of KS in MPS IVA patients relative to healthy indivi-
duals. KS can be quantified in urine and plasma and may
be helpful for screening and for following the clinical
course and efficacy of treatment [9,11]. KS levels in urine
and plasma have been shown to vary with age (with
plasma levels generally peaking between 5 to 10 years of
age and urine levels peaking between 1 and 5 years of age)
and increase with clinical severity of MPS IVA [12].
While KS is an important and treatment-related biomar-
ker to track MPSIVA disease progression and response to
ERT, it is not known whether there are additional biomar-
kers associated with MPS IVA and their relationship to KS
levels, disease severity, disease progression and response to
ERT. The goal of the current study is to identify additional
candidate biomarkers that support evaluations of disease
progression and monitoring response to ERT and examine
their relationships with levels of KS.
Methods
Analytes
To identify and evaluate potential biomarkers for MPS
IVA, this study examined 88 different analytes from
plasma samples obtained from 50 healthy adult control
subjects, 78 MPS IVA subjects not receiving ERT from
the MOR-001 study, and 20 subjects receiving ERT with
BMN 110 from the MOR-002 study. The analytes for this
study were from the Human Multi-Analyte Profile
( M A P )v 1 . 6f r o mR u l e sB a s e dM e d i c i n e( A u s t i nT X ) .
This is an 88-biomarker MAP providing quantitative
multiplexed assays covering different biological pathways.
Biomarkers included in this MAP were selected to pro-
vide a comprehensive understanding of complex drug
and disease effects. The analytes on the Human MAP
v1.6 are a pre-set panel and were not custom selected for
this particular disease study. Analysis of samples was per-
formed using the Luminex platform.
MOR-001
The MOR-001 study is a multicenter, multinational,
longitudinal clinical assessment of patients with MPS
IVA not receiving ERT. This longitudinal study aims to
catalogue the spectrum of symptoms and biochemical
abnormalities of subjects with MPS IVA. There have
been 129 subjects enrolled through 2009 [3]. Analytes
were profiled and quantified from plasma samples
obtained from the initial visit of the first 78 of MPS
IVA subjects and compared with the samples from 50
controls subjects (61% female, female age range 21-70,
mean female age 45; 39% male, male age range 24-71,
mean male age 47). Analyte profiles obtained in the
MPSIVA group were then sub-analyzed to determine if
any significant correlations existed to subject age, per-
formance in an endurance test (6 minute walk test; 6
MWT), or levels of urinary KS (uKS).
MOR-002
The MOR-002 study is a multicenter, open-label, dose-
escalation study to evaluate the safety, tolerability, and
efficacy of BMN 110 in patients with MPS IVA between
5 and 18 years of age. Twenty subjects enrolled in the
study, and 18 subjects completed 36 weeks of therapy
with weekly 4 to 5 hours intravenous infusions of BMN
110. The study used 3 consecutive 12-week dosing inter-
vals (the dose escalation phase), using the following
regimen:
Weeks 1012: 0.1 mg/kg/week
Weeks 13-24: 1.0 mg/kg/week
Weeks 25-36: 2.0 mg/kg/week
Subjects completing the 36-week dose-escalation per-
iod had the option to continue drug treatment for an
additional 36 weeks. Subjects continuing treatment after
the dose-escalation period received weekly 4 to 5 hour
intravenous (IV) infusions of BMN 110 at a dose of 1.0
mg/kg/week. Clinical outcomes included measures of
endurance (6 MWT), 3 minute stair climb test (3
MSCT) and pulmonary function (forced vital capacity
[FVC]), examined at baseline and weeks 6, 12, 18, 24,
30, 36, 48, 60, and 72 [7].
The same 88 analytes studied in MOR-001 patients
were profiled longitudinally in 20 MOR-002 study sub-
jects at baseline, 12, 24, and 36 weeks post-ERT during
the dose escalating phase. Analyte profiles were then
sub-analyzed to determine if any significant correlations
existed to subject age or performance in the 6 MWT.
Both MOR-001 and MOR-002 were approved by an
Institutional Review Board and informed consent was
obtained from all human subjects.
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T-tests were performed to check for significant differ-
ences in analytes between MPS IVA patients and unaf-
fected control subjects (for MOR-001), between older
(over 9.5 years) and younger (9.5 years or less) MPS
IVA subjects, between MPS IVA subjects with high
(> 24.6 μg/mg creatinine) and low (≤ 24.6 μg/mg creati-
nine) uKS, and between MPS IVA subjects with high
(> 235 meters) and low (≤ 235 meters) 6 MWT scores.
The specific high and low cut-off points for age, uKS
and 6 MWT scores were selected to keep the groups
statistically balanced. T-tests were also used to compare
baseline and the different time points of ERT (baseline
vs. week 12, baseline vs. week 24, and baseline vs. week
3 6 ,w e e k1 2v s .w e e k2 4 ,w e e k1 2v s .w e e k3 6 ,w e e k2 4
vs. week 36). T-tests were performed using the unpooled
variance method. For patients on ERT, analysis of var-
iance (ANOVA) was carried out across all time points,
over all samples and all analytes on the normalized data,
and subsequent Tukey results (a statistical test per-
formed after ANOVA to perform a pairwise comparison
of the means) are presented.
Results
Demographics
Table 1 summarizes the demographic information for
MPS IVA subjects from MOR-001 and MOR-002 parti-
cipating in this biomarker study. The 78 subjects
selected from the MOR-001 study for this analysis are
demographically matched to the overall MOR-001 study
population.
Comparison of MPS IVA subjects (did not receive ERT;
MOR-001) to unaffected control group
Nineteen analytes were significantly different between
these two groups at the p < 0.05 level (see Table 2). The
pattern of values for these nineteen analytes in MPS
IVA patients was different from the unaffected controls
in almost all subject samples. Three analytes were
significantly higher in MPS IVA subjects versus unaf-
fected controls, and the other 16 were significantly
lower in MPS IVA subjects compared to controls.
Analyte correlations in MPS IVA subjects not receiving
ERT
Correlation with age
Table 3 lists the 11 analytes that were significantly differ-
ent between the high (> 9.5 years) and low (≤ 9.5 years)
age groups for MPS IVA subjects. Of these, 3 were signif-
icantly higher in the older patients, and 8 were signifi-
cantly higher in the younger patients. Six of the 11
analytes were also significantly different between the high
and low uKS groups. MMP-2 was also significantly differ-
ent between MPS IVA subjects and unaffected controls
(see Table 2).
Correlations with 6 MWT score
Table 4 lists the 7 analytes that were significantly differ-
ent between the MPS IVA subjects with high versus low
6 MWT scores (> 235 meters), and the other three were
higher in patients with low 6 MWT scores (≤ 235). The
analyte insulin was also significantly different between
high and low uKS groups.
Correlations with uKS levels
Table 5 lists the 16 analytes that were significantly dif-
ferent between the MPS IVA subjects with high versus
low urinary KS. Nine of these analytes were significantly
higher in subjects with high uKS (> 24.6 μg/mg creati-
nine), and seven were significantly higher in subjects
with low uKS (≤ 24.6 μg/mg creatinine).
Analyte correlations in MPS IVA subjects post-ERT
Patients with MPS IVA treated with ERT at escalating
doses for 36 weeks demonstrated an initial increase in
pro-inflammatory and acute phase proteins, followed by
a decreased and subsequent modulation of the immune
response. Two subjects terminated the study before 12
weeks; neither subject was included in the 12 week time
point group.
Table 1 Subject demographics
Demographic Variables MOR-001 (N = 78) MOR-002 (N = 20)
Age (years) Mean (SD) 13.47 (12.41) 7.95 (2.892)
Median 9.5 7.5
Min, Max 1.0, 65.0 4.0, 16.0
Ethnicity Hispanic or Latino 3 (3.8%) 0 (0%)
Not Hispanic or Latino 75 (96.2%) 20 (100%)
Race White 41 (52.6%) 9 (45.0%)
Asian 24 (30.8%) 9 (45.0%)
Black or African American 0 (0%) 0 (0%)
Other 13 (16.7%) 2 (10%)
Gender Female 42 (53.8%) 8 (40.0%)
Male 36 (46.2%) 12 (60.0%)
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correlations post-ERT in MPS IVA
Using ANOVA to compare all analytes across all time
points (baseline vs. 12, 24, and 36 weeks of ERT), 15
analytes had highly significant changes (p < 0.01) com-
pared to baseline (pre-treatment)-see Table 6. Of these,
four analytes were also significantly different between
MPS IVA patients not receiving ERT and unaffected
controls (see Table 6). These analytes may be candidate
biomarkers for monitoring ERT response in patients
with MPS IVA.
The week 12 measures were most different from week
24 and 36, with the week 24 measures more similar to
the week 36 measures. Complement 3 is highly signifi-
cant across all comparisons (except baseline vs. week
12). Alpha-1-antitrypsin is also highly significant across
most comparisons (except baseline to week 12 and week
24 to week 36). The other tope analytes are: endothelin-
1, IgM, IL-3, IL-13, serum amyloid P, and CD40. Of
these 8 top analytes, alpha-1-antitrypsin and serum amy-
loid P are particularly promising as candidate biomar-
kers as they were significantly different between MPS
IVA and unaffected control subjects not receiving ERT
and serum amyloid P also correlated with uKS levels.
IgM is also of interest as it was significantly higher in
patients with low uKS levels and increased during ERT.
Inflammation-related analytes
An initial increase in pro-inflammatory analytes (such as
TNF-alpha) and acute phase proteins were followed by a
decrease or subsequent modulation of the immune
response (see Table 7 for longitudinal analysis and Fig-
ure 1).
Analyte correlation with age
Table 8 shows the analytes that were significantly differ-
ent between children aged 5-7 years (younger age
group) and those aged 8-10 years (older age group)
Table 2 Analytes that differ significantly between MPS IVA and unaffected control subjects
Analyte p-value
Significantly higher in MPSIVA patients versus unaffected controls
MDC (macrophage-derived chemokine 0.047
MIP-1 alpha (macrophage inflammatory protein-1 alpha)* 0.014
MMP-2 (matrix metalloproteinase-2)*† 0.003
Significantly lower in MPSIVA patients versus unaffected controls
Alpha-1-antitrypsin 0.006
Alpha-fetoprotein 0.001
C-reactive protein 0.000
EN-RAGE (extracellular newly-identified receptor for advanced glycosylation end products) 0.000
Eotoxin 0.001
Erythropoietin 0.000
Factor VII 0.028
Ferritin 0.019
IFN-gamma (interferon-gamma) 0.001
IL-RA (interleukin-1 receptor antagonist) 0.000
Leptin* 0.000
Lipoprotein (a)* 0.000
MCP-1 (monocyte chemotactic protein 1) 0.009
Myeloperoxidase 0.036
Prostatic acid phosphatase 0.000
Serum amyloid P* 0.006
* These analytes were also significantly different between the high and low uKS groups of MPS IVA patients (see table 5).
† This analyte was also significantly different between the older and younger age groups of MPS IVA patients (see table 3).
Note: The following analytes were also tested but not found to be statistically significantly different between MPS IVA and unaffected individuals: adiponectin,
alpha-2-macroglobulin, apolipoprotein A-I, apolipoprotein C-III, apolipoprotein H, apolipoprotein (a), beta-2-microglobulin, brain-derived neurotrophic factor,
calcitonin, cancer antigen 125, cancer antigen 19-9, carcinoembryonic antigen, CD40 antigen, CD40 ligand, complement C3, creatine kinase-MB, endothelin-1,
epidermal growth factor, epithelial-derived neutrophil-activating protein 78, fatty acid-binding protein (heart), fibrinogen, fibroblast growth factor basic,
granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, growth hormone, haptoglobulin, immunoglobulin A, immunoglobulin E,
immunoglobulin M, insulin, insulin-like growth factor I, intercellular adhesion molecule 1, interleukin-1 alpha, interleukin-1 beta, interleukin-2, interleukin-3,
interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-10, interleukin-12 subunit p40, interleukin-12 subunit p70, interleukin-13,
interleukin-15, interleukin-16, lymphotactin, macrophage inflammatory protein 1-beta, matrix metalloproteinase-3, matrix metalloproteinase-9, myoglobulin,
plasminogen activator inhibitor 1, pregnancy-associated plasma protein A, prostate-specific antigen (free), RANTES/CCL5 (regulated upon activation, normal T-cell
expressed and secreted), serum glutamic oxaloacetic transaminase, sex hormone-binding globulin, stem cell factor, thrombopoietin, thyroid-stimulating hormone,
thyroxine-binding globulin, tissue factor, tissue inhibitor of metalloproteinase 1, tumor necrosis factor alpha, tumor necrosis factor beta, tumor necrosis factor
receptor-like 2, vascular cell adhesion molecule-1, vascular endothelial growth factor, and von Willebrand factor.
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could be almost completely differentiated using the 6
analytes significant at the p < 0.05 level (see Table 8).
Only one of the analytes identified (alpha-1-antitrypsin)
was also significantly affected by ERT.
Age correlation with 6 MWT
Using the eight analytes identified as highly significant
between the dose/time points, only alpha-1-antitrypsin
correlated with 6 MWT score, and this was a weak nega-
tive correlation (R = -0.709) found only at week 12 (but
not weeks 24 or 36). None of the other analytes corre-
lated with the 6 MWT, although complement 3 has a
strong correlation with IgM and alpha-1-antitrypsin.
Discussion
This study represents a comprehensive analysis of biomar-
kers in MPS IVA. Understanding and identifying relevant
biomarkers for MPS IVA may help elucidate the biochem-
ical nature of the disease pathology and monitor response
to treatment. Of the 88 analytes tested, 19 analytes were
able to be differentiated between MPS IVA individuals
and unaffected controls. Five of these analytes also chan-
g e ds i g n i f i c a n t l yi nr e s p o n s et oE R Ti nt h eo v e r a l l
ANOVA analysis: alpha-1-antitrypsin, eotaxin, lipoprotein
(a), MMP-2, and serum amyloid P. Of these, only 3 were
significantly lower in MPS IVA individuals and also
increased during ERT: alpha-1-antitrypsin, lipoprotein(a),
and serum amyloid P. MMP-2 was significantly higher in
MPS IVA individuals but increased with ERT, and exo-
toxin was significantly lower in MPS IVA individuals but
decreased with ERT. Alpha-1-antitrypsin is the only one of
these candidate biomarkers that also correlated with the
clinical endpoint 6 MWT (at week 12 of treatment).
The magnitude of the number of analyte differences
seen between MPS IVA subjects and healthy controls
m a yb ee x p l a i n e db yt h er o l eG A G ss u c ha sK Sp l a yi n
cellular signaling, both as free molecules and attached to
proteins to form proteoglycans. GAGs may influence
cell division, differentiation, signal transduction, adhe-
sion, and response to growth factors. Thus, through cel-
lular signaling, GAGs may affect a variety of biological
pathways, including those both related and unrelated to
MPS IVA [13,14]. It is important to note that although
both the unaffected control group and the MPS IVA
subject group covered a large age span (1 to 65 for MPS
IVA subjects and 21 to 71 for healthy controls), the
unaffected control population had a higher average age
than the MPS IVA population, which could theoretically
account for some of the observed differences in biomar-
kers between these two groups. However, most of the
biomarkers that were significantly different between
these two groups were not significantly correlated with
age in MPS IVA patients. As well, age differences
between controls and MPS IVA subjects would not have
any effect on the other analysis, which compared results
within age groups of MPS IVA subjects rather than with
controls.
Table 3 Analytes significantly correlated with age in MPS
IVA subjects
Analyte p-value
Significantly higher in older patients (> 9.5 years) versus younger
patients
IGF-1 (insulin-like growth factor-1) 0.010
IgA (immunoglobulin A)* 0.002
IgM (immunoglobulin M)* 0.004
Significantly higher in younger patients (< 9.5 years) versus older
patients
Calcitonin 0.015
G-CSF (granulocyte colony-stimulating factor) 0.044
Growth hormone* 0.003
ICAM-1 (intracellular adhesion molecule-1)* 0.000
MMP-2 (matrix metalloproteinase-2)*‡ 0.019
TNF-alpha (tumor necrosis factor alpha)* 0.000
TSH (thyroid stimulating hormone) 0.023
VCAM-1 (vascular cell adhesion molecule-1)* 0.009
* These analytes were also significantly different between high and low uKS
groups (see Table 5).
‡This analyte was also significantly different between MPS IVA patients and
unaffected controls (see Table 2).
Table 4 Analytes significantly correlated with 6 MWT performances in MPS IVA subjects
Analyte p-value
Significantly higher in patients with high 6MWT score (> 235) versus lower scores
Apolipoprotein A1 0.011
Apolipoprotein CIII 0.001
Insulin* 0.004
Myoglobin 0.029
Significantly higher in patients with low 6MWT score (< 235) versus higher scores
Adiponectin 0.013
Alpha-2 macroglobulin 0.002
CD40 ligand (cluster of differentiation 40 ligand) 0.034
*This analyte was also significantly different between high and low uKS groups (see Table 5).
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tant biomarker for MPS IVA, with high uKS levels being
a marker for more severe disease [12], this study also
examined correlations between uKS and the candidate
biomarkers. Some, but not all of the 9 analytes that were
significantly higher in MPS IVA subjects with high uKS
changed in response to ERT. The reason for this finding
is unknown; perhaps the subset of patients with more
severe disease may have required a longer duration of
ERT to see a significant change in some analytes, or
some analytes may be correlated with pathways that do
not respond to ERT. Of the three candidate biomarkers
that were significantly lower in MPS IVA individuals and
also increased with ERT, two correlated with uKS levels
in subjects not receiving ERT. Lipoprotein(a) and serum
amyloid P levels were significantly higher in patients with
low uKS levels. Further research is needed to determine
whether this is due to an association with less severe dis-
ease or whether it is related to the fact that KS levels
decline with age [12].
Although the role of these biomarkers and their patho-
physiology with MPS IVA needs further research, three
biomarkers were identified that differentiated MPSIVA
from unaffected individuals and correlated with ERT
response: alpha-1-antitrypsin, serum amyloid P, and lipo-
protein(a). Alpha-1-antitrypsin is an acute phase protein
produced by the liver in response to stimuli such as
inflammatory mediators. Its primary physiological role is
to protect the alveolar tissue of the lungs from proteolytic
damage from enzymes such as neutrophil elastase. Defi-
ciency of alpha-1-antitrypsin can produce emphysema,
liver cirrhosis, and panniculitis [15]. Therefore, conceiva-
bly, the lower levels of alpha-1-antitrypsin seen in MPS
IVA patients may add to the lung and liver pathology
Table 5 Analytes significantly correlated with uKS levels in MPS IVA subjects
Analyte p-value
Significantly higher with high uKS (> 24.6 g/mg creatinine) versus lower levels
Alpha-2 macroglobulin† 0.029
Growth hormone† 0.003
ICAM-1 (intracellular adhesion molecule-1)† 0.007
MIP-1 alpha (macrophage inflammatory protein-1 alpha)‡ 0.022
MMP-2 (matrix metalloproteinase-2)‡ 0.024
SHBG (sex hormone-binding globulin) 0.029
TNF-alpha (tumor necrosis factor alpha)† 0.005
Thyroxine binding globulin 0.000
VCAM-1 (vascular cell adhesion molecule-1)† 0.003
Significantly higher with low uKS (< 24.6 μg/mg creatinine) versus higher levels
Brain-derived neurotrophic factor 0.045
IgA (immunoglobulin A)† 0.008
IgM (immunoglobulin M)† 0.005
Insulin§ 0.011
Leptin‡ 0.010
Lipoprotein (a)‡ 0.032
Serum amyloid P‡ 0.005
† These analytes were also significantly different between the high and low age groups.
‡ These analytes were also significantly different between MPS IVA patients and unaffected controls.
§ This analyte was also significantly different between the high and low 6MWT groups.
Table 6 Analytes that changed significantly during ERT
Analyte Effect of ERT on analyte p-value
Analytes that increased during ERT
Alpha-1-antitrypsin ‡¥ Increase 0.001
Apolipoprotein H Increase 0.021
Complement 3 ¥ Increase 0.000
Endothelin-1 ¥ Increase 0.000
Fibrinogen Increase 0.039
IgA (immunoglobulin A) Increase 0.044
IgM (immunoglobulin M) ¥ Increase 0.000
IGF-1 (insulin-like growth factor 1) Increase 0.022
Lipoprotein (a) ‡ Increase 0.037
Serum amyloid P ‡¥ Increase 0.001
von Willebrand factor ¥ Increase 0.003
Analytes that decreased during ERT
CD40 ¥ Decrease 0.002
Eotaxin ‡ Decrease 0.020
IL-3 (interleukin-3) ¥ Decrease 0.000
IL-13 (interleukin-13) Decrease 0.015
‡ These analytes were also significantly lower in MPS IVA patients compared
to unaffected controls not receiving ERT.
¥These analytes were statistically significant at the p < 0.01 level for ANOVA
comparing analytes across all time points.
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following ERT may be at least partly related to a compen-
satory response to protect the lungs from damage due to
increased proteases (MMP-2) that are clearing the
damaged tissue and GAG accumulation. Serum amyloid
P is a glycoprotein that forms a major part of serum and
plays a role in the acute phase response and complement
mediated immunity. It also facilitates the clearance of
apoptotic cells [16]. The relationship between serum
amyloid P and MPS IVA may be related to inflammation
and apoptosis.
Lipoprotein(a) is composed of the protein apolipopro-
tein(a) linked to Apo-B-100 by a disulfide bond. Elevated
lipoprotein(a) levels are associated with an increased risk
of atherosclerosis-related events such as cardiovascular
disease and stroke. Lipoprotein(a) is believed to be
involved in forming atherosclerotic plaques and enhan-
cing platelet interaction [17]. It also correlates with
inflammatory activity, as seen in patients with rheuma-
toid arthritis (RA) [18]. Lipid metabolism is altered in
inflammatory states such as RA: levels of atherogenic
lipoprotein(a) are elevated and high-density lipoprotein is
altered from its usual anti-artherogenic state to become
proinflammatory, leading to an increased risk of cardio-
vascular disease [19]. Alterations in lipid profile are seen
even up to 10 years before RA appears [20]. Given the
physiological role of lipoprotein(a), it might be expected
to contribute to the cardiovascular disease seen in MPS
IVA patients. But contrary to expectations, lipoprotein(a)
levels were lower in MPS IVA patients compared to unaf-
fected controls. Lipoprotein(a) levels increased with ERT.
This may be related to the immune response to ERT
Table 7 Longitudinal presentation of analyte data post-ERT (baseline, 12, 24, and 36 weeks).
Comparisons versus baseline
Week 12 (p < 0.01)* Week 24 (p < 0.01) Week 36 (p < 0.001)
Increased over baseline Apoliprotein CIII Alpha-1-antitrypsin Alpha-1-antitrypsin
MCP-1 Apolipoprotein CIII Apolipoprotein CIII
MMP-2 Complement 3 Complement 3
Thrombopoietin Endothelin-1 MMP-2
Fibrinogen IgM
MCP-1 Fibrinogen
MIP-1 alpha
MMP-2
Decreased over baseline Alpha-2 macroglobulin IL-4 CD40
SGOT IL-13 SGOT
VCAM-1 IL-1 alpha Apoliprotein A1
SGOT
VCAM-1
Comparison between treatment weeks
Week 12 vs. 24 (p < 0.05) Week 12 vs. 36 (p < 0.01) Week 24 vs. 36 (p < 0.05)
Increased over time Alpha-1-antitrypsin Alpha-1-antitrypsin Complement 3
Apolipoprotein H Apolipoprotein H
Complement 3 Complement 3
Endothelin-1 Endothelin-1
IgM IGF-1
IgA IgM
MIP-1 alpha Serum amyloid P
Serum amyloid P TNF-alpha
von Willebrand Factor
Decreased over time Alpha-fetoprotein Apolipoprotein A1 CD40
Fatty acid binding protein CD40
IL-3 IL-3
IL-4
IL-7
IL-13
Thrombopoietin
*T-tests were performed at a variety of different p-values including p < 0.05, p < 0.01, and p < 0.001. The significance level that gave the best separation
between groups is reported.
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biomarkers and acute phase proteins.
Although MPS disorders are not primarily associated
with clinically detectable inflammation, the pathophysiol-
o g yo fb o n ed a m a g ei nM P Sm a yi n v o l v ei n f l a m m a t o r y
cytokines such as TNF-alpha, interleukin-beta, and sub-
stances involved in Toll-like pathways [21]. As well, lyso-
somal storage of GAGs can impair autophagy, leading to
the accumulation of polyubiquitinated proteins and dys-
functional mitochondria, leading to inflammation and
apoptosis [22]. This study found higher TNF-alpha levels
in patients with high levels of uKS but there was no signif-
icant difference in TNF-alpha levels between individuals
with MPS IVA and healthy controls. This could be due to
the fact that TNF-alpha may play a role in cartilage
damage, and patients with higher KS levels have more car-
tilage damage (since KS is released when cartilage is
damaged). TNF-alpha also showed an increase at week 12
of ERT, followed by a decrease to baseline. This may be
related to an immune response to ERT, and also has paral-
lels to RA pathology. TNF-alpha is one of the main pro-
inflammatory cytokines involved in RA pathology, indu-
cing a complex cascade of inflammatory reactions that
lead to joint damage. Research suggests that TNF-alpha
plays a role in cartilage damage in RA [23]. Anti-TNF
therapy is used to target this cascade to help treat RA and
other inflammatory diseases [24]. Both RA and MPS IVA
involve damage to the cartilage, so it is not surprising that
TNF-alpha would be elevated both in RA patients and in
patients with MPS IVA that have high KS levels.
Other markers of inflammation showed mixed results.
Two pro-inflammatory markers (MDC and MIP-1
alpha) were higher and one anti-inflammatory marker
(IL-1RA) was lower in MPSIVA patients compared with
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Figure 1 The green diamonds represent the sample mean and the 95% confidence interval. The center line across each diamond
corresponds to the group mean. The vertical span of each diamond represents the 95% confidence interval for each group. The width and
height of the diamonds is proportional to the sample size at each time point with narrow and tall diamonds indicating fewer data points. The
blue lines found within the green diamonds are mean error bars corresponding to the mean of each group with error bars one standard error
above and below each group mean. The blue lines outside the diamonds represent one standard deviation above and below the group mean.
The black squares represent individual data points.
Table 8 Analyte correlation with age post-ERT
Analyte response Week 12 Week 24 Week 36
Higher in younger patients G-CSF Alpha-1-antitrypsin Beta-2 microglobulin
Ferritin
IL-1 RA
SGOT
Stem cell factor
Higher in older patients Apolipoprotein CIII None Creatine kinase-MB
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Page 8 of 10healthy controls. However, many pro-inflammatory mar-
kers such as C-reactive protein, eotaxin, IFN-gamma,
MCP-1, and serum amyloid P, were actually lower in
MPS IVA patients. EN-RAGE was also lower in MPS
IVA patients, which would be expected to indicate
lower inflammation. It could be that the pathology of
MPS IVA involves only specific inflammatory molecules,
and further understanding of these pathways will help
clarify which markers should be elevated in MPS IVA.
MPSIVA biomarker research is particularly important
now that ERT is in development for MPS IVA. Studies
in the related lysosomal storage disorders MPS I [25]
and MPS VI [26] show that early treatment with ERT
may help delay or prevent the onset of MPS symptoms.
The current biomarker study found 5 analytes that were
significantly higher in younger (aged 5 to 7 years) than
in older children (aged 8 to 10 years) after 36 weeks of
ERT: beta-2 microglobulin, ferritin, IL-1RA, SGOT, and
stem cell factor, one that was significantly lower: crea-
tine kinase-MB. As the development of ERT for MPS
IVA progresses, further research will be needed to iden-
tify potential biomarkers for younger age groups (less
than 5 years of age). Additional research may also help
clarify the role that body weight plays in Morquio bio-
markers, since patients with Morquio syndrome may
become overweight due to mobility issues. In the cur-
rent study, all subjects receiving ERT had antibodies to
rhGALNS by week 12 of treatment. This is supported
by the longitudinal biomarker evidence which shows an
initial increase in pro-inflammatory biomarkers and
acute phase proteins, followed by a decrease in the
immune responses. Therefore, some of the changes in
the listed biomarkers are likely a result of the anti-
rhGALNS immune response rather than indicators of
ERT response. It should be noted that a high level of
antibody response to ERT has been observed in other
lysosomal storage disorders including MPS I, II, and VI.
I nt h em a j o r i t yo fc a s e s ,a v a i l a b l ee v i d e n c eh a sn o t
demonstrated a correlation between antibody develop-
ment and changes in safety or efficacy [27].
Conclusions
This study identified biomarkers that may help elucidate
the biochemical nature of the disease pathology and
monitor responses to therapy. Biomarkers of particular
interest for further research include alpha-1-antitrypsin,
lipoprotein(a), and serum amyloid P. While any of these
individual analytes may be candidates for biomarkers, all
analyses were carried out using sets of analytes; indivi-
dual analytes and all possible combinations were not
tested. Follow-up laboratory tests will be necessary to
verify the candidate biomarkers and further explore their
role in MPS IVA. Future research may also help evaluate
the role of other candidate biomarkers that were not
available in the panel used for this study, such as collagen
1 and 2. The Human MAPv1.6 panel of biomarkers did
not have a comprehensive set of bone/cartilage specific
markers and therefore future studies could focus on bio-
chemical markers of skeletal abnormalities. Abnormal
levels of KS and other matrix components may directly
impact the inflammatory response. The intracellular and
extracellular accumulation of KS and ongoing damage to
certain tissues in MPSIVA appear to cause a chronic
inflammatory state with an imbalance in many physiolo-
gical systems. Future cell based or disease model studies
could shed light on the role of KS in inflammation.
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